CUSIP: 30049G104
Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
4,504,481
-
Share change
-
+224,344
-
Total reported value
-
$6,170,082
-
Put/Call ratio
-
4.5%
-
Price per share
-
$1.37
-
Number of holders
-
19
-
Value change
-
+$218,734
-
Number of buys
-
9
-
Number of sells
-
12
Quarterly Holders Quick Answers
What is CUSIP 30049G104?
CUSIP 30049G104 identifies EVOK - EVOKE PHARMA INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2021
-
Previous quarter:
Q1 2021
Recent filing periods for CUSIP 30049G104:
Institutional Holders of EVOKE PHARMA INC - COM (EVOK) as of Q2 2021
As of 30 Jun 2021,
EVOKE PHARMA INC - COM (EVOK) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,504,481 shares.
The largest 10 holders included
AIGH Capital Management LLC, VANGUARD GROUP INC, MORGAN STANLEY, Worth Venture Partners, LLC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Inc., Raymond James Financial Services Advisors, Inc., SABBY MANAGEMENT, LLC, NORTHERN TRUST CORP, and CITADEL ADVISORS LLC.
This page lists
19
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.